Academic activities
 He has supervised 8 PhD students (plus 5 ongoing), 10 Master students (plus 2
ongoing) and 8 diploma students (plus 1 ongoing)(details at Dissertations and theses).
 He participated in several post graduate master courses in Greece; currently:
Molecular Biomedicine and Clinical Biochemistry and Molecular Diagnostics.
 He has been invited to present his work to a plethora of scientific conferences (A nonexhaustive list can be found at Presentations).
 He has served as a reviewer in >38 scientific journals (IF 3.51 -16.42), as well as in
the Faculty of F1000.
 He has served as a reviewer/evaluator/rapporteur of national and international grant
proposals: ΓΓΕΤ, ΙΚΥ, ΕΛΙΔΕΚ, Alliance National de la Research (ANR), British
Lung Foundation, German-Israeli Foundation, Netherland Organization for Scientific
Research (NWO), Cyprus RIF, RIKEN/FANTOM, Welcome Trust, European
commission/Marie Curie.
 In 2018, he received the National Academy of Athens research award for his work
on the role of ATX in liver fibrosis and cancer.
 His lab is recognized as an “excellent” host center for respiratory research (RESPIRE4)

Other activities
 He pioneered (2000-2007) the use of DNA microarrays and related bioinformatic tools
and set up the first expression profiling service unit in Greece offering services to
Fleming and external researchers.
 He is a co-founder of Biomedcode Hellas, a Fleming spin-off for preclinical evaluation
studies and novel drug development and he has applied for eight patents (6 active).
 He is a founding member of the Scientific Society for Rare Diseases & Orphan Drugs
(SSRDOD).
 He supervised (2005-2011) the creation of several mouse databases, in the context of
various international collaborations aiming to promote mouse database functionalities
and interoperability.
 He setup the Respiratory Unit of BSRC Fleming and various animal models of lung
diseases, allowing the investigation of pathogenetic genes and therapeutic
interventions.
 He setup two biobanks with idiopathic pulmonary fibrosis (IPF) and lung cancer
patient samples (sera, plasma, BALF, tissue), promoting translational research.
 He set up at the local MS facilities lipidomics, the quantification of more than 70
(lyso)phospholipids in biologic fluids and tissues.
 He has signed >42 material transfer agreements for proprietary materials (genetically
modified mice and monoclonal antibodies)
 He established a drug discovery pipeline for the identification of novel ATX
inhibitors, that can be applied for the pharmacological targeting of other novel drug
targets.
 His work provided the scientific proof of principle for the ongoing clinical trials on
ATX inhibition in IPF patients.